A research team led by Professor Hongzhe SUN, Chair Professor from the Department of Chemistry, Faculty of Science, in collaboration with Dr Pak-Leung HO, Director of the HKU Carol Yu Centre for Infection from the Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong (HKU) discovers that by repurposing an antirheumatic gold drug, auranofin (AUR), “last-resort” antibiotics can be resensitized for treatment of infections caused by multidrug-resistant superbugs including bloodstream infections, pneumonia and wound infections.
The findings provide insights into development of inorganic pharmaceutics and new therapeutic approach for superbug infections. The ground-breaking findings on antimicrobial resistance (AMR) are now published in a leading multidisciplinary science journal, Nature Communications and a related patent has been filed in the US.
Antibiotics are medicines designed to kill bacteria and treat bacterial infections. Antibiotic resistance occurs when bacteria adjust in response to the misuse or overuse of these medicines and it has become one of the biggest public health challenges in this era. At least 2.8 million people get an antibiotic-resistant infection annually in the US, and more than 35,000 people die from it.
The most commonly used antibiotics to treat bacterial infections are β-lactams antibiotics, such as cephalosporins and carbapenems. However, their clinical efficacies have been greatly challenged as bacteria produce a resistant determinant that are capable of hydrolysing nearly all β-lactams antibiotics, named metallo-β-lactamases (MBLs). Therefore, the “last-line” antibiotic colistin (COL) has re-emerged as a therapeutic option in response to the outbreak of infections caused by extensively multidrug-resistant Gram-negative pathogens since the mid-1990s. Unfortunately, the efficacy of COL has also been seriously compromised in the regular treatment of lethal bacterial infections, owing to the emergence of another resistant determinant, mobilized colistin resistance (MCR) enzyme in 2015. Owing to the vast structural difference and mode of mechanisms between the two enzymes, it remains an extreme difficulty of adopting a general therapy for infections caused by MBL(s) and MCR(s) co-producing pathogens. As said by Dr Tedros ADHANOM GHEBREYESUS, Director-Genera of World Health Organization (WHO), “As we gather more evidence, we see more clearly and more worryingly how fast we are losing critically important antimicrobial medicines all over the world.” Thus, in clinic context, common infections with these “superbugs” may soon be untreatable, which will severely endanger public health system and leave clinicians with virtually no therapeutic options.
With little remission from the therapeutic reliance on the current pipeline of β-lactam antibiotics and COL, the combination therapy consisting of an antibiotic resistance and an antibiotic-resistance breaker offers promising options to narrow the gap between multidrug-resistant bacteria and the development of new antibiotics. The research team previously discovered an anti-peptic ulcer bismuth drug, colloidal bismuth subcitrate, potently inhibits MBL activity and re-sensitize MBL-positive bacteria to β-lactam antibiotics. The related works were published in Nature Communication in 2018.
Their new findings follow this widely-recognized discovery, and identifies AUR serves to revive the potency of both carbapenem such as meropenem (MER), and COL through a series of screening on an Escherichia coli (denoted as E. coli CKE), clinically collected by Dr Ho Pak Leung in Queen Mary Hospital in Hong Kong, that co-produces two key resistant determinants, MBLs and MCRs. They found that AUR could entirely inhibit the hydrolytic activity of MBL through targeting crucial cysteine residue in the enzyme active site and functionally disrupt MCR-1 by targeting phosphorylated Thr285 residue via a distinct metal displacement route. Significantly, the novel combinatorial therapy allows the dose of either MER or COL to be lowered by 32~64 folds to achieve the same level of effectiveness against superbug E. coli CKE, and the development of level of resistant determinant to be significantly slowed down, which will dramatically extend the life cycle of currently used antibiotics.
In the mouse model, combination therapy comprising AUR and COL is highly effective in eradicating multidrug-resistant bacteria in peritonitis infection model. Co-administration with AUR restored the in vivo efficacy of COL, with over 10-fold reduction in MCR-1-producing Klebsiella pneumoniae loads in mouse liver and spleen in comparison to antibiotic alone. More significantly, all the mice that were systemically infected by superbug E. coli CKE were saved after 5-day treatment of AUR-COL combination.
“Considering the well-recorded safety of in human, AUR as well as related gold drugs as a dual-inhibitor of MBLs and MCRs would largely broaden the therapeutic options in treating the infections caused by multidrug-resistant superbugs,” said Professor Sun.